tirzepatide for heart failure with preserved ejection fraction and obesity obesity: emerging metabolic therapeutic strategies | Diabetology & Metabolic Syndrome Tirzepatide benefits obese HFpEF patients

Most users see this number drop by 2 to 4 points within the first few weeks

It is being recategorized

Mean Change in Body Weight (%) from Baseline to Week 72 (WEGOVY 7.2 mg Injection Study 8) Observed values for patients completing each scheduled visit, and estimates with multiple imputations from retrieved dropouts (RD-MI)

3 That pattern supports what we see clinically: when hair shedding happens alongside GLP-1 therapy, it often tracks more closely with the degree and speed of weight loss , rather than a simple drug causes hair loss relationship

And legislators should recognize the difference

How do GLP-1 agonists work